Barclays PLC lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 12.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 122,849 shares of the specialty pharmaceutical company's stock after buying an additional 14,061 shares during the quarter. Barclays PLC owned approximately 0.22% of Supernus Pharmaceuticals worth $4,442,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Franklin Resources Inc. increased its holdings in shares of Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock valued at $987,000 after acquiring an additional 2,121 shares during the last quarter. Principal Financial Group Inc. increased its stake in Supernus Pharmaceuticals by 5.4% during the third quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company's stock valued at $8,899,000 after purchasing an additional 14,566 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Supernus Pharmaceuticals by 40.6% during the third quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company's stock worth $7,901,000 after purchasing an additional 73,118 shares during the period. Burney Co. lifted its position in shares of Supernus Pharmaceuticals by 603.4% in the 4th quarter. Burney Co. now owns 83,152 shares of the specialty pharmaceutical company's stock worth $3,007,000 after buying an additional 71,331 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 60.5% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 66,306 shares of the specialty pharmaceutical company's stock valued at $2,398,000 after buying an additional 25,004 shares during the period.
Insider Activity at Supernus Pharmaceuticals
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. 9.30% of the stock is owned by insiders.
Supernus Pharmaceuticals Stock Performance
Shares of NASDAQ:SUPN traded up $0.66 during trading hours on Friday, hitting $33.11. The stock had a trading volume of 83,691 shares, compared to its average volume of 546,864. The stock's fifty day simple moving average is $31.86 and its 200 day simple moving average is $34.97. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of 30.91 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28.
Analyst Upgrades and Downgrades
SUPN has been the subject of a number of research reports. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.
View Our Latest Analysis on SUPN
Supernus Pharmaceuticals Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Recommended Stories
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
